Anti-cancer activity of plant-produced HPV16 E7 vaccine
Anti-cancer activity of plant-produced HPV16 E7 vaccine
复制标题
DOI：
10.1016/j.vaccine.2007.01.018
复制
发表时间：
2007-04-20
期刊：
影响因子：
5.5
通讯作者：
Venuti, Aldo
中科院分区：
文献类型：
--
作者：
Massa, Silvia;Franconi, Rosella;Venuti, Aldo
来自人乳头瘤病毒（HPV）的E7癌蛋白是一种有吸引力的抗癌疫苗候选物。在本研究中，我们将hpv16e7编码序列（野生型或诱变序列E7GGG）与热细胞梭菌（Clostridium thermocellum）的β - 1,3,4 -葡糖苷酶（LicKM）进行融合，并利用瞬时表达系统在烟叶植物中产生。靶抗原被纯化，并在小鼠中评估其作为预防性和治疗性候选疫苗的潜力。两种融合蛋白均诱导e7特异性IgG和细胞毒性t细胞反应，并保护小鼠免受表达e7的肿瘤细胞的攻击。此外，当这些植物产生的抗原在攻击后给药时，可以阻止肿瘤的发展。(c) 2007 Elsevier Ltd.版权所有。
The E7 oncoprotein from Human Papilloma Virus (HPV) is an attractive candidate for anti-cancer vaccine development. In this study, we engineered HPV16 E7 coding sequence (wild type or mutagenized sequence, E7GGG) as fusions to beta-1,3-1,4-glucanase (LicKM) of Clostridium thermocellum and produced in Nicotiana benthamiana plants using a transient expression system. Target antigens were purified and evaluated in mice for their potential as prophylactic and therapeutic vaccine candidates. Both fusion proteins induced E7-specific IgG and cytotoxic T-cell responses and protected mice against challenge with E7-expressing tumor cells. Furthermore, when administered after challenge, these plant-produced antigens prevented tumor development. (c) 2007 Elsevier Ltd. All rights reserved.